Abstract
Catheter ablation for rhythm control in atrial fibrillation has been recognized as an established treatment. Patients with atrial fibrillation suffer from an increased risk of thromboembolic events. Long-term stroke risk and mortality have been shown to be reduced after catheter ablation, still the procedure per se is associated with an additive peri-procedural thromboembolic risk. Maintenance of the thrombotic - bleeding equilibrium in such patients during interventional procedures is compelling. Lack of data from randomized studies along with the recent introduction of novel oral anticoagulants in clinical practice has resulted in a wide variance of antithrombotic treatment approaches. Procedural interruption of anticoagulants, switching of anticoagulation scheme (i.e. from novel oral anticoagulants to vitamin K antagonists), bridging with heparin, timing of re-initiation of therapy and/or utilization of novel oral anticoagulants have all been points of dispute. In the present review we present the available data regarding optimal peri-procedural anticoagulation strategies in patients undergoing catheter ablation for atrial fibrillation.
Keywords: Radiofrequency, cryoablation, VKA, NOAC, warfarin, dabigatran, rivaroxaban, apixaban.
Current Pharmaceutical Design
Title:Peri-procedural Anticoagulation in Catheter Ablation for Atrial Fibrillation: A Review
Volume: 23 Issue: 9
Author(s): Dimitrios A. Vrachatis*, Georgios Giannopoulos, Charalambos Kossyvakis, Vasiliki Panagopoulou, Manolis Vavuranakis, Theodore G. Papaioannou, Stamatina Pagoni, Vlasios N. Pyrgakis, Michael W. Cleman and Spyridon G. Deftereos
Affiliation:
- Department of Cardiology, “G. Gennimatas” General Hospital of Athens, 154 Mesogion ave., 115 27, Athens,Greece
Keywords: Radiofrequency, cryoablation, VKA, NOAC, warfarin, dabigatran, rivaroxaban, apixaban.
Abstract: Catheter ablation for rhythm control in atrial fibrillation has been recognized as an established treatment. Patients with atrial fibrillation suffer from an increased risk of thromboembolic events. Long-term stroke risk and mortality have been shown to be reduced after catheter ablation, still the procedure per se is associated with an additive peri-procedural thromboembolic risk. Maintenance of the thrombotic - bleeding equilibrium in such patients during interventional procedures is compelling. Lack of data from randomized studies along with the recent introduction of novel oral anticoagulants in clinical practice has resulted in a wide variance of antithrombotic treatment approaches. Procedural interruption of anticoagulants, switching of anticoagulation scheme (i.e. from novel oral anticoagulants to vitamin K antagonists), bridging with heparin, timing of re-initiation of therapy and/or utilization of novel oral anticoagulants have all been points of dispute. In the present review we present the available data regarding optimal peri-procedural anticoagulation strategies in patients undergoing catheter ablation for atrial fibrillation.
Export Options
About this article
Cite this article as:
Vrachatis A. Dimitrios*, Giannopoulos Georgios, Kossyvakis Charalambos, Panagopoulou Vasiliki, Vavuranakis Manolis, Papaioannou G. Theodore, Pagoni Stamatina, Pyrgakis N. Vlasios, Cleman W. Michael and Deftereos G. Spyridon, Peri-procedural Anticoagulation in Catheter Ablation for Atrial Fibrillation: A Review, Current Pharmaceutical Design 2017; 23 (9) . https://dx.doi.org/10.2174/1381612822666161205115101
DOI https://dx.doi.org/10.2174/1381612822666161205115101 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Systematic Review on Levosimendan in Paediatric Patients
Current Vascular Pharmacology Inflammatory Markers Associated With Diabetes Mellitus – Old and New Players
Current Pharmaceutical Design Cisplatin Properties in a Nanobiotechnological Approach to Cancer: A Mini-Review
Current Cancer Drug Targets Experimental Study on the High Speed Performance of Bearings
Recent Patents on Mechanical Engineering Ximelagatran: An Oral Direct Thrombin Inhibitor for Anticoagulant Therapy
Letters in Drug Design & Discovery <i>In Vivo/Ex Vivo</i> EPR Investigation of the Brain Redox Status and Blood-Brain Barrier Integrity in the 5xFAD Mouse Model of Alzheimer's Disease
Current Alzheimer Research Motion Analysis of the Carotid Artery Wall and Plaque Using B-Mode Ultrasound
Vascular Disease Prevention (Discontinued) Myelin Injury and Degraded Myelin Vesicles in Alzheimer’s Disease
Current Alzheimer Research Review of Recent Toroidal Rotary Engine Patents
Recent Patents on Mechanical Engineering Heparanase Patents: Dim Past and Bright Future
Recent Patents on Inflammation & Allergy Drug Discovery Purines as Neurotransmitters and Neuromodulators in Blood Vessels
Current Vascular Pharmacology Betaxolol Hydrochloride Loaded Chitosan Nanoparticles for Ocular Delivery and their Anti-glaucoma Efficacy
Current Drug Delivery Mechanisms of Vascular Hyporesponsiveness in Septic Shock
Current Vascular Pharmacology Advances in Antiplatelet Therapy for Stroke Prevention: the New P2Y12 antagonists
Current Drug Targets Apoptosis Imaging to Monitor Cancer Therapy: The Road to Fast Treatment Evaluation?
Current Pharmaceutical Biotechnology 7-Difluoromethyl-5, 4’-Dimethoxygenistein Reverses LPC-Induced Apoptosis of HUVE-12 Cells Through Regulating Mitochondrial Apoptosis Pathway
Current Signal Transduction Therapy Cytokine-Induced Inflammatory Liver Injuries
Current Molecular Medicine The Versatile Stress Protein Mortalin as a Chaperone Therapeutic Agent
Protein & Peptide Letters Effects of Physical Exercise on Depressive Symptoms and Biomarkers in Depression
CNS & Neurological Disorders - Drug Targets Recent Advancements in Liposome-Based Strategies for Effective Drug Delivery to the Brain
Current Medicinal Chemistry